title: Olanzapine orally disintegrating tablet: a review of efficacy and compliance.
abstract: Medication nonadherence, especially in psychiatric disorders, has been associated with treatment failure and other negative outcomes. Orally disintegrating formulations have been developed as an alternative to improve medication adherence. This report reviews the properties, efficacy, and safety profile of olanzapine as an orally disintegrating tablet, and explores their association with medication compliance compared with standard oral formulation. Medical literature, published on orally disintegrating formulation of olanzapine identified using Pubmed and EMBASE, was used. Additional references were identified from the reference lists of published articles. Bibliographical information, including contributory unpublished data, was also requested from the company developing the drug. Studies evaluating the biostability, biodisposability, pharmacokinetics, efficacy, and safety of orally disintegrating olanzapine as treatment of patients with psychiatric disorders were reviewed. Measurement tools included the Positive and Negative Syndrome Scale (PANSS), Clinical Global Impressions-Severity (CGI-S), Simpson-Angus Scale (SAS), Abnormal Involuntary Movement Scale, and Nursing Assessment of Medication Acceptance (NAMA). Orally disintegrating olanzapine, an effective atypical antipsychotic with an acceptable safety profile, can facilitate the burden of treatment on patients and caregivers due to its ease of administration. This is especially important in diseases such as schizophrenia and bipolar disorder, which can be chronic and require long-term treatment.
authors.affiliation: Servicio de Psiquiatría, Hospital San Igualada, Barcelona, Spain.
authors.forename: Luis
authors.initials: L
authors.lastname: San
authors.forename: Marta
authors.initials: M
authors.lastname: Casillas
authors.forename: Antonio
authors.initials: A
authors.lastname: Ciudad
authors.forename: Inmaculada
authors.initials: I
authors.lastname: Gilaberte
mesh_terms: D000284:Administration, Oral; D014150:Antipsychotic Agents / Q000008:administration & dosage* / Q000493:pharmacokinetics; D001569:Benzodiazepines / Q000008:administration & dosage* / Q000493:pharmacokinetics; D001682:Biological Availability; D001714:Bipolar Disorder / Q000188:drug therapy*; D002626:Chemistry, Pharmaceutical; D016503:Drug Delivery Systems; D006801:Humans; D000077152:Olanzapine; D017063:Outcome Assessment, Health Care; D010349:Patient Compliance; D012559:Schizophrenia / Q000188:drug therapy*; D012995:Solubility; D013607:Tablets
chemical_list: D014150:Antipsychotic Agents; D013607:Tablets; D001569:Benzodiazepines; D000077152:Olanzapine
references.citation: Psychopharmacology (Berl). 2004 Sep;175(3):389-90
references.pmid: 15322727
references.citation: Prog Neuropsychopharmacol Biol Psychiatry. 2007 Mar 30;31(2):541-2
references.pmid: 17029723
references.citation: Pharmacoeconomics. 2000 Aug;18(2):106-24
references.pmid: 11067646
references.citation: J Am Pharm Assoc (Wash). 2000 Jul-Aug;40(4):475-85
references.pmid: 10932456
references.citation: J Child Adolesc Psychopharmacol. 2004 Winter;14(4):617-20
references.pmid: 15662155
references.citation: J Clin Psychiatry. 2005 Nov;66(11):1493-4; author reply 1494
references.pmid: 16420093
references.citation: Drugs. 2001;61(1):111-61
references.pmid: 11217867
references.citation: Drug Saf. 2006;29(6):550-2; author reply 552
references.pmid: 16752937
references.citation: J Clin Psychopharmacol. 2007 Aug;27(4):392-4
references.pmid: 17632224
references.citation: Schizophr Bull. 1997;23(4):637-51
references.pmid: 9366000
references.citation: Schizophr Bull. 1994;20(2):297-310
references.pmid: 7916162
references.citation: Am J Psychiatry. 2004 Apr;161(4):692-9
references.pmid: 15056516
references.citation: Int J Neuropsychopharmacol. 2003 Jun;6(2):97-102
references.pmid: 12890301
references.citation: Drugs. 2004;64(23):2709-26
references.pmid: 15537371
references.citation: Can J Psychiatry. 2004 May;49(5):297-302
references.pmid: 15198465
references.citation: Schizophr Bull. 1995;21(3):419-29
references.pmid: 7481573
references.citation: Hum Psychopharmacol. 2007 Jan;22(1):11-5
references.pmid: 17191265
references.citation: Psychiatr Serv. 1999 May;50(5):667-73
references.pmid: 10332904
references.citation: Acta Psychiatr Scand Suppl. 2000;(407):83-6
references.pmid: 11261648
references.citation: Arch Gen Psychiatry. 1974 Nov;31(5):603-8
references.pmid: 4374155
references.citation: Cochrane Database Syst Rev. 2005 Apr 18;(2):CD003729
references.pmid: 15846678
references.citation: Gen Hosp Psychiatry. 2008 Jul-Aug;30(4):367-71
references.pmid: 18585542
references.citation: J Psychosoc Nurs Ment Health Serv. 2004 May;42(5):44-8
references.pmid: 15182049
references.citation: World J Biol Psychiatry. 2010 Oct;11(7):894-903
references.pmid: 20653494
references.citation: J Clin Psychiatry. 2006;67 Suppl 5:19-23
references.pmid: 16822093
references.citation: Medicina (Kaunas). 2006;42(12):1006-12
references.pmid: 17211109
references.citation: JAMA. 1990 Nov 21;264(19):2511-8
references.pmid: 2232018
references.citation: Eur Psychiatry. 2001 Aug;16(5):293-8
references.pmid: 11514132
references.citation: Can J Psychiatry. 2002 Oct;47(8):771-4
references.pmid: 12420656
references.citation: J Clin Psychiatry. 2003;64 Suppl 16:10-3
references.pmid: 14680413
references.citation: J Nerv Ment Dis. 2004 Jun;192(6):421-7
references.pmid: 15167405
references.citation: J Clin Pharmacol. 2006 Feb;46(2):164-71
references.pmid: 16432268
references.citation: Schizophr Bull. 1987;13(2):261-76
references.pmid: 3616518
references.citation: J Clin Psychopharmacol. 1997 Dec;17(6):472-7
references.pmid: 9408810
references.citation: Biol Psychiatry. 2001 Mar 15;49(6):487-99
references.pmid: 11257234
references.citation: Eur J Cancer Care (Engl). 2007 May;16(3):289-90
references.pmid: 17508951
references.citation: J Clin Psychopharmacol. 2006 Jun;26(3):333-5
references.pmid: 16702903
references.citation: Pharmacogenet Genomics. 2005 Apr;15(4):195-200
references.pmid: 15864111
references.citation: J Clin Psychiatry. 2006 Jul;67(7):1114-23
references.pmid: 16889456
references.citation: J Clin Psychiatry. 2003 Feb;64(2):119-22
references.pmid: 12633119
references.citation: J Pharm Pharmacol. 1998 Apr;50(4):375-82
references.pmid: 9625481
references.citation: Pharmacoepidemiol Drug Saf. 2003 Jul-Aug;12(5):423-4
references.pmid: 12899119
references.citation: Hum Psychopharmacol. 2008 Apr;23(3):211-6
references.pmid: 18219624
references.citation: Actas Esp Psiquiatr. 2007 Jan-Feb;35(1):47-51
references.pmid: 17323225
references.citation: CNS Drugs. 2005;19(2):147-64
references.pmid: 15697328
references.citation: Patient Prefer Adherence. 2007 Dec 20;1:19-27
references.pmid: 19956444
references.citation: Encephale. 2002 May-Jun;28(3 Pt 1):266-72
references.pmid: 12091789
references.citation: Am J Physiol. 1994 Jan;266(1 Pt 2):R284-91
references.pmid: 8304552
references.citation: Am J Med. 1997 Feb 17;102(2A):43-9
references.pmid: 9217586
references.citation: Eur Psychiatry. 2007 Oct;22(7):453-4
references.pmid: 17761403
references.citation: N Engl J Med. 2005 Aug 4;353(5):487-97
references.pmid: 16079372
references.citation: Clin Ther. 2007 Feb;29(2):290-304
references.pmid: 17472821
references.citation: Schizophr Bull. 1996;22(1):69-82
references.pmid: 8685665